348 related articles for article (PubMed ID: 26138912)
1. Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model.
Louie AV; Haasbeek CJ; Mokhles S; Rodrigues GB; Stephans KL; Lagerwaard FJ; Palma DA; Videtic GM; Warner A; Takkenberg JJ; Reddy CA; Maat AP; Woody NM; Slotman BJ; Senan S
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):82-90. PubMed ID: 26138912
[TBL] [Abstract][Full Text] [Related]
2. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer.
Liang W; Zhang L; Jiang G; Wang Q; Liu L; Liu D; Wang Z; Zhu Z; Deng Q; Xiong X; Shao W; Shi X; He J
J Clin Oncol; 2015 Mar; 33(8):861-9. PubMed ID: 25624438
[TBL] [Abstract][Full Text] [Related]
4. Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Jacobs CD; Mehta K; Gao J; Wang X; Salama JK; Kelsey CR; Torok JA
Clin Lung Cancer; 2022 Mar; 23(2):177-184. PubMed ID: 34301453
[TBL] [Abstract][Full Text] [Related]
5. Development and external validation of a nomogram to predict overall survival following stereotactic body radiotherapy for early-stage lung cancer.
Baker S; Bakunina K; Duijm M; Hoogeman MS; Cornelissen R; Antonisse I; Praag J; Heemsbergen WD; Nuyttens JJ
Radiat Oncol; 2020 Apr; 15(1):89. PubMed ID: 32321553
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment Modified Glasgow Prognostic Score Predicts Clinical Outcomes After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer.
Kishi T; Matsuo Y; Ueki N; Iizuka Y; Nakamura A; Sakanaka K; Mizowaki T; Hiraoka M
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(3):619-26. PubMed ID: 26068494
[TBL] [Abstract][Full Text] [Related]
8. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer.
Widder J; Postmus D; Ubbels JF; Wiegman EM; Langendijk JA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e291-7. PubMed ID: 21640503
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer.
Takeda A; Sanuki N; Eriguchi T; Kaneko T; Morita S; Handa H; Aoki Y; Oku Y; Kunieda E
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):257-63. PubMed ID: 23570699
[TBL] [Abstract][Full Text] [Related]
10. The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.
Duijm M; Oomen-de Hoop E; van Voort van der Zyp N; van de Vaart P; Tekatli H; Hoogeman M; Senan S; Nuyttens J
Radiother Oncol; 2021 Mar; 156():223-230. PubMed ID: 33418006
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.
Boily G; Filion É; Rakovich G; Kopek N; Tremblay L; Samson B; Goulet S; Roy I;
J Thorac Oncol; 2015 Jun; 10(6):872-82. PubMed ID: 26001140
[TBL] [Abstract][Full Text] [Related]
12. Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms.
Zindler JD; Jochems A; Lagerwaard FJ; Beumer R; Troost EGC; Eekers DBP; Compter I; van der Toorn PP; Essers M; Oei B; Hurkmans CW; Bruynzeel AME; Bosmans G; Swinnen A; Leijenaar RTH; Lambin P
Radiother Oncol; 2017 May; 123(2):189-194. PubMed ID: 28237400
[TBL] [Abstract][Full Text] [Related]
13. Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
Warner A; Dahele M; Hu B; Palma DA; Senan S; Oberije C; Tsujino K; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; De Ruyck K; De Dios NR; Bradley JD; Rodrigues G
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):612-20. PubMed ID: 26867890
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
15. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
[TBL] [Abstract][Full Text] [Related]
16. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
Shultz DB; Diehn M; Loo BW
Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
[TBL] [Abstract][Full Text] [Related]
17. Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Ye L; Shi S; Zeng Z; Huang Y; Hu Y; He J
Jpn J Clin Oncol; 2018 Feb; 48(2):160-166. PubMed ID: 29253245
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiotherapy (SABR) for non-small cell lung cancer.
Iyengar P; Westover K; Timmerman RD
Semin Respir Crit Care Med; 2013 Dec; 34(6):845-54. PubMed ID: 24258574
[TBL] [Abstract][Full Text] [Related]
19. Survival time following resection of intracranial metastases from NSCLC-development and validation of a novel nomogram.
Ji X; Zhuang Y; Yin X; Zhan Q; Zhou X; Liang X
BMC Cancer; 2017 Nov; 17(1):774. PubMed ID: 29157203
[TBL] [Abstract][Full Text] [Related]
20. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy.
Dehing-Oberije C; Yu S; De Ruysscher D; Meersschout S; Van Beek K; Lievens Y; Van Meerbeeck J; De Neve W; Rao B; van der Weide H; Lambin P
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):355-62. PubMed ID: 19095367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
